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The subventricular zone (SVZ) neural stem cell
niche contains mixed populations of stem cells,
transit-amplifying cells, and migrating neuroblasts.
Deciphering how endogenous signals, such as
hormones, affect the balance between these cell
types is essential for understanding the physiology
of niche plasticity and homeostasis. We show that
Thyroid Hormone (T3) and its receptor, TRa1, are
directly involved in maintaining this balance. TRa1
is expressed in amplifying andmigrating cells. In vivo
gain- and loss-of-function experiments demonstrate
first, that T3/TRa1 directly repress Sox2 expression,
and second, that TRa1 overexpression in the niche
favors the appearance of DCX+ migrating neuro-
blasts. Lack of TRa increases numbers of SOX2+
cells in the SVZ. Hypothyroidism increases propor-
tions of cells in interphase. Thus, in the adult SVZ,
T3/TRa1 together favor neural stem cell commitment
and progression toward a migrating neuroblast
phenotype; this transition correlates with T3/TRa1-
dependent transcriptional repression of Sox2.
INTRODUCTION
Neural stem cells (NSCs) are defined by their ability to self-renew
and differentiate, giving rise to progenitor cells, then neurons,
oligodendrocytes, and astrocytes (Doetsch et al., 2002). A
controlled balance of proliferation and differentiation is required
to maintain homeostasis of the neural stem niche and the
proportions of stem cells (type B cells), transit-amplifying
progenitors (TAPs or type C cells), and migrating neuroblasts
(type A cells) (Doetsch et al., 1999). An important question is
how hormone signaling modulates adult stem/progenitor cellfunction, thereby affecting the physiological plasticity of adult
neurogenesis. The biologically active form of thyroid hormone
(tri-iodo-thyronine, T3) is well documented for its orchestration
of complex homeostatic and developmental effects, from
amphibian metamorphosis to mammalian brain development
(Forrest et al., 1996). In humans, insufficient T3 during develop-
ment induces neurological damage and cretinism (Pitt-Rivers,
1963). In the adult brain, T3 and its receptor, TRa1, are required
for the full potential of cell proliferation in the SVZ (Lemkine
et al., 2005).
We analyzed the molecular basis underlying the effects of the
TRa1/T3 complex in the SVZ. Expression of the transcription
factor TRa1 was found in TAPs, beingmaintained in neuroblasts.
By the use of a nonviral gene transfer method that allows trans-
fection of the stem cell and progenitor cell populations (Lemkine
et al., 2002), overexpression of TRa1 promoted differentiation of
the transfected cells into neuroblasts and entry into the rostral
migratory stream (RMS). This transfection method allowed us
to follow transcriptional regulations in the SVZ. We demonstrate
that the effect of TRa1 on commitment involves direct repression
of Sox2 by TRa1 binding to the Sox2 Regulatory Region 1
(SRR1). Finally, induction of hypothyroidism in mice showed
that TRa1-mediated regulation of Sox2 is T3 dependent.
SOX2 is implicated in controlling neural progenitor mainte-
nance (Graham et al., 2003; Pevny and Nicolis, 2010), and
progenitor commitment requires Sox2 repression to allow tran-
scription of proneural factors (Favaro et al., 2009; Sikorska
et al., 2008). Thus, the identification of factors involved in Sox2
repression could represent a significant advance in the under-
standing of the cellular pathways governing stem cell to progen-
itor to neuroblast progression in the SVZ. However, although
several pathways activating Sox2 expression are known—e.g.,
CBF/NFY (Wiebe et al., 2000), Oct3/4 (Chew et al., 2005), FGF
(Chew et al., 2005), EGFR (Hu et al., 2009), Shh, Gli2 (Takanaga
et al., 2009), HIF (Moreno-Manzano et al., 2010), and Ars2
(Andreu-Agullo et al., 2012)—to our knowledge, our data is the
first to identify a signaling pathway favoring neurogenesis by
direct repressive action on Sox2.Cell Stem Cell 10, 531–543, May 4, 2012 ª2012 Elsevier Inc. 531
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T3/TRa1 Form a Neurogenic Switch in the Adult SVZRESULTS
TRa1 Is Expressed in TAPs and Migrating Neuroblasts
Only one T3 binding receptor subtype, TRa1, is expressed in the
SVZ (Lemkine et al., 2005). To clarify its role, fluorescent immu-
nohistochemistry (FIHC) using established markers for migrating
neuroblasts (DCX+) and TAPs (DLX2+) was used to identify SVZ
cell types expressing TRa1 (Pastrana et al., 2011; Tavazoie et al.,
2008). As shown in Figures 1A–1F, TRa1 colocalizes with either
DCX+ (Figures 1A–1C) or DLX2+ cells (Figures 1D–1F). If the
large majority of DCX+ neuroblasts express TRa1, some (about
5%) DLX2+ TAPs were negative for TRa1 (Figures 2A–2H). It is
thus probable that DLX2 expression is anterior to TRa1, and
that TRa1 expression appears in TAPs and is maintained in neu-
roblasts (Figure 2I). As regards colocalization of TRa1 and SOX2,
a marker widely expressed in the SVZ niche (Tavazoie et al.,
2008), we observed a strong inverse correlation in the expression
of SOX2 and TRa1, SOX2high cells being TRa1low (Figures 1G–1I).
SOX2high cells were also DLX2low (arrows in Figures 1M–1O).
Similarly, DCX+ clusters of migrating neuroblasts were consis-
tently SOX2low (Figures 1J–1L and Figure S1H). Taken together,
the observations suggest first, that TRa1 expression largely co-
localizes with DLX2 in TAPs, persisting after transition to the
migrating neuroblast stage; and second, that these cellular tran-
sitions are accompanied by a progressive reduction in intensity
of SOX2 labeling (Figures 1G–1O). To bolster this result on recip-
rocal levels of expression of TRa1 and SOX2, we used TRa+/0
knockin animals in which a b-gal cassette reflects TRa expres-
sion (Figures S1A–S1G). b-gal FIHC confirmed that cells ex-
pressing high levels of SOX2 had weak b-gal (TRa) signals
(Figures S1D–S1F). Quantification of cells with high or low
marker expression showed three populations: SOX2high/TRalow
or SOX2low/TRahigh and a few SOX2high with moderate TRa
expression (Figure S1G). We used GFAP/SOX2/TRa1 triple
FIHC to label type B cells (Tavazoie et al., 2008) and confirm
that TRa1 is not found in B cells (Figures S1I–S1L). Taken
together, the FIHC data show that TRa1 expression appears in
TAPs and is maintained in DCX+ neuroblasts (Figures 1A–1C).
These findings are summarized in Figure 2I.
TRa1 Loss of Function in the SVZ Increases Sox2mRNA
and Numbers of SOX2-Expressing Cells
Given the strong expression of TRa1 in TAPs and neuroblasts,
we postulated that TRa1 expression could be involved in stem
cell commitment. To test this hypothesis, we examined the
SVZmorphology of TRa0/0mice. Adult TRa0/0mutants displayed
broader SVZs than controls (Figures 3A and 3B), with signifi-
cantly increased numbers of SVZ SOX2+ cells (50.7 ± 5.2 in
controls versus 64.9 ± 6.5 in TRa0/0, Figure 3C). To examine
the acute effects of TRa1 loss, siTRa1 was introduced by stereo-
taxic injection into the lateral ventricles of adult wild-type mice.
At 24 hr posttransfection of siTRa1, qPCR showed significant
downregulation of TRa1 mRNA. This effect was specific, as
TRa2 expression was unaffected (Figure 3D). As a positive
control, we confirmed that CyclinD1 mRNA was upregulated
following downregulation of TRa1, as previously shown (Hassani
et al., 2007). The modest (25%), but significant, downregulation
of TRa1 can be explained by local delivery of siTRa1, which is
diluted by dissection of the SVZ area. Nonetheless, the approach532 Cell Stem Cell 10, 531–543, May 4, 2012 ª2012 Elsevier Inc.was sufficiently efficient to reveal significant upregulation of
several stem cell/TAP markers such as Sox2, Nestin, and Msi1
mRNAs following siTRa1 transfection (Figure 3E). TRa1 repres-
sion is thus correlated with increased levels of neural progenitor
markers.
TRa1 Gain of Function in the SVZ Represses Sox2
Expression and Increases Numbers of DCX+ Clusters
Next the reverse experiment was performed, i.e., TRa1 overex-
pression in the adult SVZ. We used a polyethylenimine (PEI)-
based in vivo gene transfer method that transfects stem cells
and TAP populations (Lemkine et al., 2002). Stereotaxic injection
of a plasmid expressing GFP into the lateral ventricles of adult
mice resulted in GFP expression mainly in Nestin+ and GFAP+
cells (Figures S2A and S2B), corresponding to NSCs and TAPS.
A schema of the experimental protocol used to overexpress
TRa1 is shown in Figure 4A. A rat TRa1-expressing plasmid
(TRa1) was stereotaxically injected into the lateral ventricles of
adult mice, which were sacrificed at either 48 hr or 4 days post-
transfection. At 48 hr posttransfection, qPCR analysis confirmed
increasedTRa1mRNA levels followingTRa1overexpressionwith
no effect on TRa2 levels (Figure 4B). Both Sox2 and CyclinD1
mRNA decreased following TRa1 overexpression (Figure 4B).
To trace transfected cell fate, TRa1 (or a control plasmid, with
the same promoter as TRa1) was coinjected with CMV-GFP. At
48 hr posttransfection of TRa1, strong TRa1 expression was
found in GFP+ cells (see arrow showing GFP+, Figure 4E, and
TRa1, Figure 4G). As hypothesized, SOX2 was strongly
repressed by TRa1 overexpression (arrow, Figures 4F–4H).
Quantifying the proportion of transfected cells (GFP+) express-
ing SOX2 after TRa1 overexpression showed SOX2 expression
in 42.8% ± 8.9% of the transfected cells in controls, whereas
TRa1 decreased 2-fold SOX2+ cells in the transfected popula-
tion (21.2% ± 1.5%) (Figure 4C).
Because TRa1 overexpression was correlated with downre-
gulation of SOX2, we questioned what effect TRa1 expression
had on cell fate. Sagittal sections of brains cotransfected with
TRa1/GFP or Control/GFPweremade at 4 days posttransfection
and GFP FIHC was used to follow cell fate. Cells having received
TRa1 were found in DCX+ clusters at the entry to the RMS
(Figures 4L–4P). In contrast, in controls, GFP transfected cells
remained close to the lateral ventricle (Figures 4J and 4K). Inter-
estingly, GFP expression was stronger in the TRa1 compared to
control-transfected cells. Because TRa1 appears to favor a neu-
roblast phenotype, it is plausible that the decreasedGFP expres-
sion in controls is due to dilution of plasmid in the proliferating
population.
Taken together, TRa1 loss and gain of function suggest a role
of TRa1 in Sox2 repression and NSC commitment.
The TRa1 Ligand, T3, Represses Sox2 Expression
in the SVZ
TRa1 activity is modulated by its ligand, T3. To investigate the
effects of T3 on Sox2 expression and on NSC commitment, we
used hypothyroid mice lacking T3 (see Experimental Proce-
dures). qPCR analysis of the SVZ of hypothyroid mice treated
with saline or T3 showed that Sox2 expression was significantly
downregulated in adults (Figures 5A and 5B) and neonatal mice
(Figure S3A) by T3 treatment.
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Figure 1. TRa1 Is Expressed in Transit-Amplifying Progenitors (TAPs) and Neuroblasts of the Adult Mouse SVZ
Confocal imaging (A–O). Dorsal SVZ areaswere analyzed at similar levels on coronal sections along the anterior-posterior axis (see Experimental Procedures, and
schema in Figure S2).
(A–C) Fluorescent Immunohistochemistry (FIHC) for TRa1 (green) and DCX (red). DCX labels migrating neuroblasts. Arrowheads indicate TRa1+/DCX+ clustered
cells. Arrows indicate TRa1+ cells negative for DCX. All DCX+ cells are TRa1+.
(D–F) FIHC for TRa1 (green) and DLX2 (red). DLX2 is expressed in TAPs in the adult SVZ. Arrowheads indicate TRa1+/DLX2+ cells. Arrows indicate TRa1+ cells
negative for DLX2. Most DLX2+ cells are TRa1+, but DLX2 is only expressed in a subset of TRa1+ cells. In those cells, TRa1 expression is positively correlated
with DLX2 expression.
(G–I) FIHC for TRa1 (green) and SOX2 (red). SOX2 is widely expressed in the adult SVZ. Cells expressing high TRa1 levels express low or undetectable SOX2
levels (arrowheads). Cells expressing high SOX2 levels express low or no TRa1 levels (arrows).
(J–O) FIHC for SOX2 (green) and DCX (red) (J–L) or DLX2 (red) (M–O). For imaging, we used the same parameters for SOX2 in all series. (J–L) DCX+ cells express
low levels of SOX2 (arrowheads). (M–O) Cells expressing high levels of DLX2 express low or undetectable levels of SOX2 (arrowheads) whereas cells with high
SOX2 levels express low or undetectable DLX2 levels (arrows).
Bars: 50 mm. Nuclei are labeled with DAPI (blue). (See also Figure S1).
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T3/TRa1 Form a Neurogenic Switch in the Adult SVZTo evaluate effects of hypothyroidism on cell division and
commitment in the SVZ, we performed PH3 and DLX2 immunos-
taining on control and hypothyroid brains. High, homogenous
labeling for PH3, a mitotic cell marker, distinguishes activelydividing, mitotic cells, whereas labeling in foci characterizes cells
in interphase (Van Hooser et al., 1998). PH3-expressing cells
were quantified accordingly. Compared to controls, hypothyroid
mice had reduced proportions of PH3high, mitotic cells andCell Stem Cell 10, 531–543, May 4, 2012 ª2012 Elsevier Inc. 533
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Figure 2. TRa1 Expression Appears in TAPs in the Adult Mouse SVZ
Confocal imaging (A–H) on coronal sections. Areas for image acquisition were from dorsal SVZ (A–D) and ventral SVZ (E–H). FIHC was used to analyze TRa1
(green) and DLX2 (red) coexpression. DLX2 is expressed in TAPs in the adult SVZ. Dotted lines circle DLX2+ cells where the TRa1 signal did not exceed
background. DAPI (blue) labels nuclei. Arrowheads indicate TRa1+/DLX2+ cells. Diagram (I) summarizes TRa1 expression during NSC commitment. Bars: 20 mm.
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T3/TRa1 Form a Neurogenic Switch in the Adult SVZincreased numbers of cells in interphase with PH3 in foci (Figures
5C–5F). To assess effects of hypothyroidism on TAP (DLX2+
cells) commitment, DLX2+ cells were quantified. Hypothy-
roidism reduced the proportions of cells with high levels of
DLX2 compared to controls (Figures 5G–5J). Thus, hypothy-
roidism increases cells in interphase within the niche, affecting
the TAP population, as shown by the decrease in DLX2 bright534 Cell Stem Cell 10, 531–543, May 4, 2012 ª2012 Elsevier Inc.cells. Together these findings suggest a role for T3 in the exit
from quiescence.
The Sox2 SRR1 Enhancer Is Repressed by TRa1/T3
Regulation of Sox2 expression involves SRR1 and SRR2 (Fig-
ure 6A), two elements located upstream and downstream,
respectively, of the Sox2 coding region (Tomioka et al., 2002).
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Figure 3. TRa1 Loss of Function Increases the SOX2+ Population in Adult Mouse SVZ and Expression of Neural Stem Markers
(A and B) SOX2 FIHC (magenta) on SVZs from wild-type (WT) or TRa0/0 adult mice.
(C) The number of SOX2+ cells within the SVZ of WT and TRa0/0 mice (light gray and dark gray, respectively) were quantified (see Experimental Procedures).
TRa0/0 mice had a significantly higher proportion of SOX2+ cells (around 30% more) compared to controls.
(D and E) siRNA-based transient TRa1 knockdown in WT adult mouse SVZ. (D) siTRa1 downregulates TRa1, but not TRa2, mRNA levels. (E) Transient TRa1
knockdownupregulatesSox2 andCyclinD1. TheNSCandTAPmarkersNestin andMsi1 are also upregulated at 24 hr posttransfection compared to controls. Each
experiment was reproducedR3 times (n = 4), providing similar results. Pooled data (nR 12) are shown with means ± SEMs. Statistical analysis used nonpara-
metric, exact permutation tests (Cytel Studio software). *p < 0.05, **p < 0.01. Bars: 25 mm. Nuclei are labeled with DAPI (blue). St, striatum; LV, lateral ventricle.
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T3/TRa1 Form a Neurogenic Switch in the Adult SVZBoth SRR1 and SRR2 show species-wide conservation, notably
between human and mouse (Tomioka et al., 2002). To analyze
the functional role of TRa1 and T3 in regulating Sox2 expression,
we used luciferase constructs under the control of the minimal
promoter region (Tomioka et al., 2002; Miyagi et al., 2006) (Fig-
ure S4B), or one of the enhancer regions, either SRR1 or SRR2
(Figure 6B). Gene transfer in newborns is faster to perform than
in adult mice, so in order to build an assay with a suitably large
set of biological replicates, gene transfer was done in newborns.
Moreover, Sox2 expression is also regulated by T3 in newborn
mouse SVZ (Figure S3A). To identify the cell types transfected
by PEI in the newborn mouse SVZ, we vectorized CMV-eGFP
plasmids and examined cellular localization of GFP. FIHC at
24 hr posttransfection showed that transfected (GFP-express-
ing) cells were largely SOX2 positive (Figures S3B–S3J).
Because most SOX2high cells have low TRa1 (Figure 1G;
Figures S1A–S1F, S1G, and S1J), we needed to ensure that suffi-
cient TRa1 was present when examining T3 effects on Sox2 tran-
scription. Thus, TRa1 was cotransfected with SRR1-luc or
SRR2-luc so that we could analyze T3-dependent regulation.
Both SRR1-luc and SRR2-luc were downregulated by 20% to
30% (p < 0.01) in SVZ of hypothyroid mice 24 hr after T3 treat-
ment (Figure 6C, left panels). In contrast, T3 treatment did notmodify transcription from the proximal promoter construct
(Sox2-luc, Figure S4B), indicating that the T3-dependent element
or elements regulating Sox2might be within SRR1 and/or SRR2.
To confirm the specific role of endogenous TRa1 on activity of
the two Sox2 enhancers, in vivo knockdown of endogenous
TRa1 in wild-type animals (Figure 6C) or rescue of TRa1 in
TRa0/0 mice (Figure 6D) was done. Cotransfection of shTRa1
(Hassani et al., 2007) along with SRR1-luc or SRR2-luc doubled
transcription (p < 0.01) from both constructs (Figure 6C, panels
on right), compared to a control shRNA with the same promoter
as shTRa1 (see Experimental Procedures). This result consoli-
dates the concept that TRa1 represses the activity of the
SRR1 and SRR2 enhancers. Furthermore, rescue of TRa1 (by
TRa1 transfection) in the SVZ of TRa0/0 mice significantly
reduced transcription from both SRR1-luc and SRR2-luc (p <
0.05), compared to a control plasmid with the same promoter
as TRa1, (Figure 6D), confirming that TRa1 regulates the activity
of both enhancers.
Sox2 Is a Direct Target Gene of TRa1
TRa1/T3-mediated repression of Sox2 could be a direct, tran-
scriptional effect, or it could be indirect. Direct repression would
involve the binding of TRa1 to a thyroid hormone responseCell Stem Cell 10, 531–543, May 4, 2012 ª2012 Elsevier Inc. 535
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Figure 4. TRa1 Overexpression Reduces the SOX2+ Population in Adult Mouse SVZ and Promotes Neuroblast Entry into the RMS
(A) Schema of experimental design: TRa1 plasmid (TRa1) or PSG5 vector (pControl) were mixed with CMV-eGFP and stereotaxically injected into adult mouse
SVZ. Two (B–I) or four (J–P) days after transfection, brains were used for qPCR (B) or for preparing coronal or sagittal sections (C–P) so as to determine the fate of
the transfected cells in the lateral ventricle and RMS.
(B) qPCR analysis of SVZ dissection shows that TRa1 transfection increases TRa1mRNA and decreases Sox2 and CyclinD1mRNA levels 48 hr posttransfection.
Note that overexpression of TRa1 did not affect TRa2 expression. n R 8 per group, means ± SEM are given. Statistical analysis used nonparametric, exact
permutation test (Cytel Studio software). *p < 0.05.
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T3/TRa1 Form a Neurogenic Switch in the Adult SVZelement (TRE) in an enhancer. In silico examination of mouse
SRR1 and SRR2 showed two areas containing candidate nega-
tive TREs (nTREs) in SRR1: TRE1/2, containing two TREs, and
TRE3 (Figure 7A). No candidate TRE was found in SRR2. To
determine if T3-dependent repression involved interaction of
TRa1with SRR1, ChIP assays were performed on SVZ dissected
from hypothyroid newbornmice, treatedwith or without T3. TRa1
was associated with TRE1/2 in T3-treated, but not untreated,
mice (Figure 7B). No TRa1 binding was found on the irrelevant
control regions of Sox2 with or without T3 (Figure 7B). To deter-
mine the functional significance of the TRE in SRR1, site-
directedmutagenesis was used. As shown in Figure 7C, whereas
T3 significantly repressed transcription from the intact construct
(p < 0.001), T3 repression of SRR1 transcription was lost on
mutation of TRE1, confirming the ChIP data, which demon-
strates a direct interaction of TRa1 with SRR1. Further, mutation
of TRE2 did not modify T3-dependent regulation of SRR1 (data
not shown), delimiting the T3/TRa1 interaction to the SSR1
TRE1 area. To bolster the physiological relevance of these
results, we examined whether T3 repression of SRR1 was dose
dependent. Significant repression was found at the lowest
dose (25 ng T3/g b.w.), with maximal repression (about 45% of
control) being found between 0.25 and 2.5 mg T3/g b.w.
(Figure S4C).
DISCUSSION
These data show that in the adult SVZ, T3 and TRa1, together,
favor NSC commitment and progression toward amigrating neu-
roblast phenotype. This commitment switch correlates with
T3/TRa1-dependent transcriptional repression of Sox2. To our
knowledge, this study is the first description of an endogenous,
hormonal signaling pathway acting on NSC commitment and
migration. Clarifying how a centrally regulated, but widely distrib-
uted, endocrine signal is integrated and interpreted in a tissue-
and cell-specific context is vital to understanding the physiology
of stem cell niches. Hormonal control of stem cell niches has
been shown in germinal stem cells of fruit flies (Gancz et al.,
2011) and in shoot stem cells in plants (Zhao et al., 2010), but
not in mammals.
The establishment of the role of TRa1/T3 in NSC progression
toward commitment derives from a series of in vivo morpholog-
ical and molecular studies. As recently emphasized (Pastrana
et al., 2011), despite their various strengths, in vitro assays
such as the neurosphere-forming assay have certain limitations,
including their establishment on the basis of proliferation, which
may not be limited to bona fide stem cells and thereby introduce
a bias to progenitors. Another drawback is that in vitro models
lose the complex cellular architecture and its intricate relation-(C) Quantification of SOX2+ cells following transfection of TRa1 or pControl. Pe
overexpression. The experiment was repeated three times (n = 4), providing simi
permutation test for multiple samples (Cytel Studio software).
(D–I) FIHC on coronal sections following transfection of TRa1/CMV-eGFP (pContr
TRa1+ (magenta) cell (E and G) that is negative for SOX2 (F). Arrowheads in (F)–
(J–P) FIHC on sagittal sections of control or TRa1-transfected brains. (J and K) In c
and (M) are high magnifications of the boxed areas (dotted lines) in (J) and (L), re
cells (GFP+ cells in green) is observed entering the RMS. (N–P) The group of TRa
(red) (O).
Representative brains are shown, n = 4 per condition. Bars: (D–I) = 10 mm; (J–P)ships with the ventricles, cerebral spinal fluid, and the vascular
system (Tavazoie et al., 2008). Other biases can arise from
changes induced by nonphysiological concentrations of growth
factors added for culture. Hence, our focus on in vivo, physiolog-
ical approaches, including nonviral gene transfer in the SVZ
(Lemkine et al., 2002, 2005) and siRNA vectorization in vivo (Has-
sani et al., 2007). FIHC was used to follow expression of markers
within the intact SVZ, comparing wild-type mice to mice lacking
TRa or euthyroid mice to hypothyroid mice.
A first element of determining how TRa1/T3 act on neurogen-
esis in the adult SVZ (Lemkine et al., 2005) was to establish the
cell types expressing receptor TRa1. TRa1 was found in
DLX2+ TAPs and DCX+ migrating neuroblasts, suggesting that
its expression correlates with commitment. To test the hypoth-
esis that TRa1 is implicated in consolidating the TAP phenotype
and promoting transition to neuroblast phenotypes, we exam-
ined the effect of targeted delivery of TRa1 to the SVZ popula-
tion. Overexpression of TRa1 induced differentiation into DCX+
neuroblasts that entered the RMS, confirming the role of TRa1
in favoring differentiation transitions. This finding raised the
question of the molecular targets underlying TRa1- and
T3-induced changes.
Having observed an inverse correlation between SOX2 and
TRa1 expression, and given that Sox2 is an early marker of the
NSC lineage (Bergsland et al., 2011), we hypothesized that
TRa1 expression represses Sox2, allowing progression of
TAPs to neuroblasts. Using FIHC for SOX2 and b-gal as a TRa
read-out, we noted three populations of cells (Figure S1G):
Sox2high/TRalow, Sox2low/TRahigh, and a smaller population
with high levels of SOX2 and intermediate b-gal (TRa) levels. Ac-
cording to current thinking, the SOX2high cells are probably
NSCs, whereas SOX2low cells represent TAPs. The smaller, third
population with high SOX2 and intermediate TRa1 levels could
represent a transition stage where SOX2 and TRa1 are coex-
pressed. This observation echoes the finding that overexpres-
sion of TRa1 repressed SOX2 expression in 50% of transfected
cells (Figure 4C). An explanation for both results is that Sox2
repression by TRa1 requires T3. Thus, cells that do not respond
to an increase in TRa1 by the decrease in Sox2/SOX2 probably
have no available T3, a factor that will be governed by cell-
specific expression of activating and inactivating deiodinases
(Williams and Bassett, 2011).
This hypothesis is supported by gain- and loss-of-function
experiments showing that T3/TRa1 together downregulate
Sox2. This regulation is dose dependent and direct. Mutating
a negative TRE in the SRR1 regulatory region abrogated
T3/TRa1 repression of transcription from SRR1. Further, ChIP
analysis showed T3-dependent association of TRa1 with
SRR1. T3 also downregulated SRR2. This area does not containrcentages of double-labeled SOX2+ and GFP+ cells decrease following TRa1
lar results. Values represent means ± SEM. **p < 0.01 by exact nonparametric
ol/CMV-eGFPwas used for controls). Arrows in (E)–(H) indicate a GFP+ (green)/
(I) indicate a SOX2+ cell that is negative for GFP/TRa1.
ontrols, cells transfected with pControl (GFP+, green) are limited to the SVZ. (K)
spectively. (L–P) In a TRa1-transfected brain, a group of overexpressing TRa1
1/CMV-eGFP-expressing cells in (M) also express the neuroblast marker DCX
= 50 mm. (See also Figure S2.)
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Figure 5. T3 Represses Sox2 Expression and Modulates Cellular Proliferation in the SVZ, Affecting the TAP Population
(A) Schema of experimental design. SVZ of hypothyroid adult mouse brains were dissected 24 or 48 hr post T3/T4 treatment (controls received NaCl).
(B) Sox2mRNA quantified by qPCRwas normalized againstGapdh using the DDCtmethod. Sox2 levels are given as a function of control levels. Pooled data from
three experiments are given, means ± SEM (nR 12). Statistical analysis used nonparametric, exact permutation test (Cytel Studio software). *p < 0.05. (See also
Figure S3).
(C–J) FIHC for PH3 (C–E) and DLX2 (G–I) on coronal sections of control (CTRL) (C and G) and hypothyroid (Hypo) (E and I) mouse brain. Dotted squares in (C) and
(E) denote regions magnified in insets (C0 and E0) where PH3 is in red and nuclei are in blue (DAPI). Cells in G2 phase have punctuated PH3 staining (see
arrowheads, C, C0, E, and E0), whereas cells in M phase have dense uniform PH3 staining (see arrows, C, C0, and E). As shown in (D) and (F), hypothyroidism is
associated with decreased proportion of high PH3+ cells, compared to controls. Dotted squares (in G and I) denote regions magnified in insets (G0 and I0 ) in which
DLX2 is in red and nuclei are in blue (DAPI). Two populations of DLX2+ cells are observed: DLX2-high+ cells (see arrows, G0 and I0) and DLX2-low+ cells (see
arrowheads in G0 and I0). Hypothyroidism is associated with a decrease of the proportion of high DLX2+ cells compared to controls (H versus J). Bars: I = 100 mm;
I0 = 10 mm.
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SRR2 contains a Sox2/Oct4 binding box activated by SOX2 itself
(Tomioka et al., 2002). Thus, SRR2 repression by T3 could entail
T3-mediated decrease of SOX2 protein. The findings that
T3/TRa1 promote commitment and repress Sox2 are in accor-538 Cell Stem Cell 10, 531–543, May 4, 2012 ª2012 Elsevier Inc.dance with demonstrations that Sox2 repression correlates
with neural differentiation in vitro (Cimadamore et al., 2011 ; By-
lund et al., 2003).
Interestingly, our data indicate that TRa1 knockdown with
siRNA increases not only Sox2 levels but also CyclinD1 mRNA
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respectively (see Experimental Procedures).
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SRR1-Luc or SRR2-Luc cotransfected with TRa1 into lateral ventricles of hypothyroid wild-type newborn mice. In each case, mice received T3 or saline. Both
SRR1-Luc and SRR2-Luc are significantly downregulated by T3. Right panel: SRR1-Luc or SRR2-Luc was cotransfected with shTRa1-expressing vectors in the
lateral ventricles of euthyroid wild-type newbornmice. shTRa1 significantly increases SRR1-Luc and SRR2-Luc activity as compared to control-plasmid-injected
brains.
(D) In TRa0/0 homozygous mice, cotransfection of TRa1 represses transcription from SRR1-Luc and SRR2-Luc.
In all cases, representative experiments are shown (means ± SEMs). Statistical analysis used nonparametric, exact permutation test (Cytel Studio software). *p <
0.05, **p < 0.01, ***p < 0.001. Each experiment was performed in triplicate (n = 10 wild-type; n = 6, TRa0/0). (See also Figure S4.)
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T3/TRa1 Form a Neurogenic Switch in the Adult SVZlevels. Previous data showed repression of CyclinD1 expression
by TRa1/T3 in the neonatal SVZ (Hassani et al., 2007). Lange
et al. (2009) have shown that CyclinD1 downregulation in the
SVZ lengthens the cell cycle, which is a necessary prerequisite
to promote neuronal differentiation. Taking these results
together, we propose that the double-pronged repression of
Sox2 and CyclinD1 by TRa1/T3 promotes differentiation of
progenitors to a more committed phenotype.These demonstrations of the role of TRa1 in adult neurogene-
sis lead to consideration of the brain phenotypes of mice lacking
TRa (TRa0/0 mice) or bearing TRa mutants. Kapoor et al. (2010)
examined hippocampal neurogenesis in mice with a TRa1
mutant that acts as an apo-receptor causing receptor-mediated
brain hypothyroidism. These mice show reduced hippocampal
neurogenesis, memory impairment, depressive behavior, and
anxiety (Venero et al., 2005; Pilhatsch et al., 2010). TheseCell Stem Cell 10, 531–543, May 4, 2012 ª2012 Elsevier Inc. 539
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(A) Schema of positions and putative TRE sequences in mouse SRR1. Three candidate TREs are shown (capital letters). Primers (underlined) used in PCR for
detection of TREs in the ChIPs products encompassed TRE1 and 2 together or TRE3 alone.
(B) qPCR quantification of ChIP assays on SVZ from hypothyroid newborn mice treated with or without T3 for 6 hr. Samples were immunoprecipitated with TRa1
antibody and amplified with Sox2 TRE1/2, TRE3, or irrelevant control primers. For negative controls, samples were processed without antibody. Data are
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run at least twice, providing similar results. Pooled data are given, means ± SEM, *p < 0.05.
(C) Transcriptional repression of SRR1 by T3 requires an intact TRE1. Site-directed mutagenesis was used to mutate TRE1. Transcription from the wild-type (left
panel) andmutated constructs (right panel) was comparedwith saline () or T3 (+). A representative experiment, reproduced three times, is shown (means ± SEM,
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dysfunction seen in hypothyroid humans (Samuels, 2008), and
second, to the potential implication of impaired adult neurogen-
esis in depression (David et al., 2009; Lledo, 2009).
A major question arising now is how availability of the active TR
ligand, T3, affects homeostasis and plasticity of the adult neuro-
genic niche. Induction of hypothyroidism in adults increased the
proportion of SVZ cells held in interphase, G2, decreasing the
proportion of cells with high PH3 labeling. This result echoes
the demonstration by Lemkine et al. (2005) using other markers
(BrdU and Ki67) and showing that hypothyroidism blocks, and
T3 reactivates, cell cycling in the adult SVZ. The additional infor-
mation provided here is that hypothyroidism leads to an increase
of cells in interphase, suggesting a potential role of T3 in the exit
fromquiescence.Thishypothesis iscorroboratedby thedecrease
of DLX2+, highly proliferative TAPs, in response to T3 deficiency.
In turn, these observations raise questions of how T3 avail-
ability is determined spatiotemporally in the SVZ and the patho-
logical consequences of changes in availability, i.e., T3 excess or
absence. T3 availability is determined by deiodinase activity (Wil-540 Cell Stem Cell 10, 531–543, May 4, 2012 ª2012 Elsevier Inc.liams and Bassett, 2011). In the brain T3 production from the pro-
hormone thryoxine (T4) is catalyzed by deiodinase type 2 (D2),
whereas deiodinase type 3 (D3) promotes degradation of T4 or
T3 into inactive forms (Ko¨hrle, 2000). Future studies will be
needed to clarify physiological control of T3 production, use,
and degradation in neurogenic zones. Notably, it is important
to determine which cells in the SVZ express each of the deiodi-
nases and whether these same cells also express membrane
transporters for TH (Friesema et al., 2006).
T3 availability and stemness are linked to pathology, notably
tumorigenesis. D3 expression increases in certain cancers (Den-
tice et al., 2009). Oppel et al. (2011) found Sox2 in glioma cells,
where its expression is associated with a less-differentiated
phenotype. Given the role of T3/TRa1 signaling in not only
NSCs, but also intestinal stem cells (Kress et al., 2009, 2010),
such findings argue for analysis of whether T3 signaling and
TRa1-controlled gene networks are involved in adult stem cell
transitions to cancer stem cells.
In conclusion, this work underlines how an endocrine signal,
T3, by repressing Sox2 expression, acts as a switch to activate
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T3/TRa1 Form a Neurogenic Switch in the Adult SVZNSC commitment. The absence of TH signaling limits the gener-
ation of neuroblasts, leading to an accumulation of Sox2+
progenitors. Synchronous repression of Sox2, CyclinD1 (Has-
sani et al., 2007), and c-myc (Lemkine et al., 2005) will facilitate
commitment and differentiation of the progenitor cell population.
This demonstration of the role of T3 in controlling stemness
opens up novel research perspectives, ranging frombasic issues
such as understanding physiological controls governing the
amount of T3 available in stem cell niches to potential applica-
tions in treatment of pathological conditions.
EXPERIMENTAL PROCEDURES
Animals
All animal studies were conducted according to the principles and procedures
described in Guidelines for Care and Use of Experimental Animals.
TRa0/0 mice (from ENS, Lyon, France, Gauthier et al., 2001), lacking TRa1,
TRa2, TR Da1, and TR Da2, were maintained on a 129/Sv strain. The DNA
construct for gene targeting was engineered to associate disruption of Thra
with an in-frame insertion of the LacZ gene. Wild-type 129/Sv mice were
from Charles River Laboratories (L’Arbresle, France). Only male mice were
used for adult studies.
PTU and TH Treatments
To induce hypothyroidism in newborn mice, pregnant female OF1 mice
(Janvier, Le Genest St. Isle, France) were given iodine-deficient food contain-
ing 6-n-propyl-2-thiouracil (PTU) (at 0.15%, from Harlan Teklad, Madison, WI)
and PTU (0.5 g/l) diluted in drinking water 7 days before the predicted day of
birth. Hypothyroidism in adult mice was induced with iodine-deficient food
(PTU: 0.15%) and PTU in drinking water (0.5 g/l) for 2 weeks. To evaluate TH
effects, T3 (2.5 mg/g b.w.) diluted in physiological solution was injected subcu-
taneously in newborn mice, or T3/T4 (0.3/0.012 mg/g b.w.) was given intraper-
itoneally in adults along with T4 in drinking water (12 mg/ml). Controls received
NaCl (0.9%) and tap water.
Plasmids
The murine Sox2 regulatory regions 1 and 2 (SRR1 and SRR2 [4485/3778
and +2072/+3681, respectively]), subcloned into Tk-Luc reporter plasmid
(Stratagene) (Tomioka et al. (2002), were a kind gift of Dr. A. Okuda (Saitama,
Japan). Two putative TREs present in SRR1 were mutated in the SRR1-Luc
construction using the QuikChange II XL Site-directedMutagenesis kit (Strata-
gene, La Jolla, CA).
The TRa1 expression vector containing the main domain of rat TRa1 was
subcloned intopSG5 (Stratagene) (Guissoumaet al., 2002). Theplasmiddriving
transcription of a shRNA against TRa1 from a CMV-H1 hybrid promoter has
been described (Hassani et al., 2007). The GFP expression plasmid contains
the GFP coding sequence under a CMV promoter (Clonetech, Palo Alto, CA).
Formulation of Polyethylenimine/DNA Complexes, and Stereotaxic
Injections
Endotoxin-free plasmid DNA (Genomed, Research Triangle Park, NC) was
diluted in 5% glucose and complexed with in vivo-jetPEI (Polyplus transfec-
tion; ratio of 6 PEI nitrogen per DNA phosphate, as described in Goula et al.,
1998). Stereotaxic injection into the lateral ventricles of newborn mice brains
was as described (Hassani et al., 2005) using a single injection (1 mg DNA in
2 ml) per lateral ventricle of newborn mice. Mice were sacrificed and the SVZ
was dissected 24 hr later. Luciferase assays were done on brain homoge-
nates. Ten animals were injected per group, and each SVZwas analyzed sepa-
rately for luciferase activity (i.e., n = 20 SVZ per group).
Adult OF1 mice (8 weeks old, Janvier) were anaesthetized with V-tranquile
(2 mg/kg b.w.; Imalgen, Ceva Sante´ Animal) followed by ketamine (100 mg/
kg b.w.; Imalgen, Merial). The animals were transfected by unilateral stereo-
taxic injection (5 ml) into the right ventricle (0.2 mm posterior to bregma line,
1.1 mm lateral, and 2.2 mm deep from the pial surface; see Lemkine et al.,
2005 for details). Analgesia treatment was performed usingMeloxicam (formu-
lated as Metacam from Boehringer Ingelheim).Formulation of siRNA Complexes
siRNA against pGL2 (for control group) or TRa1 (siTRa1) was synthesized by
QIAGEN (for sequence, see Hassani et al., 2007). siRNA (24 pmol per animal)
was diluted in glucose (5%) and complexed with monocationic lipid
(INTERFERin IC10 from Polyplus-transfection) at a ratio of 15 monocationic
lipid nitrogens per RNA phosphate. Stereotaxic injections were performed as
above.
FIHC
Mice were deeply anesthetized with Pentobarbital (130 mg/kg, Sanofi) then
perfused (3 ml/min) with saline solution (0.9%). Brains were dissected and
fixed in paraformaldehyde (2%) in PBS (0.1 M, pH 7.4) at 4C overnight
(O/N), cryoprotected in sucrose (30%), embedded in OCT, frozen, and stored
(80C). FIHC used cryostat coronal or sagittal sections (30 mm). Floating brain
sections were washed (33 10 min) with PBS in multiwell plates. Blocking was
done by incubation (1 hr) in normal donkey serum (10%). Slides were incu-
bated O/N at 4C with the following primary antibodies: rabbit anti-SOX2
(Chemicon, 1:200) or goat anti-SOX2 (Santa Cruz, 1:200). Rabbit TRa1 anti-
body was from Rockland (1:200 O/N at 4C). Goat anti-b-galactosidase anti-
body (Cappel, 1:300) was incubated for 1 hr at room temperature after two
glycine pretreatments (0.1M, 5 min). Rabbit anti-PH3 (Millipore, 1/300); guinea
pig anti-DCX (Millipore, 1:300), guinea pig anti-DLX2 (Kuwajima et al., 2006;
1:3,000) and mouse anti-GFP (Roche, 1:300) was used. Fluorescent
secondary antibodies (Invitrogen) were as follows: Alexa Fluor 647 nm donkey
anti-rabbit (1:500), Alexa Fluor 594 nm donkey-anti-guinea pig (1:500), Alexa
Fluor 488 nm donkey anti-rabbit (1:500), and Alexa Fluor 594 nm donkey
anti-goat (1: 500) for 2 hr at room temperature. Finally, brain sections were
mounted onto SuperFrost/Plus glass slides (Fisher) and air-dried before being
mounted with ProLong Gold antifade reagent with the nuclear marker DAPI
(Invitrogen). For imaging, we used a LSM 710 confocal microscope and
ApoTome system (Carl Zeiss, Thomwood, NY).
Signal Intensity Quantification
Cell counts (PH3-, DLX2-, and SOX2+ cells) were done on coronal (0.7–1.2
anterior to bregma) or sagittal (30 mm) sections and carried out double-blindly
by two observers. For each marker, all positive cells in SVZ were counted on
three consecutive slides per brain (n = 3 per group).
DLX2+ cells were sorted into two populations based upon the level of their
fluorescence intensity. Regions of interest (ROI) were defined and analyzed
using FIJI software (ImageJA 1.43h, http://rsb.info.nih.gov/ij). Gray level
threshold was stabilized at 225. The ratio of each subpopulation (DLX2-high
or -low; PH3 punctuate or PH3 high) is reported as a function of all the
DLX2- or PH3+ cells, respectively, counted in the SVZ.
In Vivo ChIP
Hypothyroid pups (1 day postnatal) were treated with T3 or vehicle and sacri-
ficed 6 hr later. SVZs were dissected and six SVZs were pooled, yielding about
40 mg of tissue. DNA-protein complexes were isolated as described (Decherf
et al., 2010). Samples were fixed in 1% formaldehyde solution and sonicated.
Control and T3-treated samples were used for ChIP with anti-TRa1 antibodies
(Thermo Scientific, Rockford, USA) or without antibody (negative control).
Precipitated DNA fragments were purified. DNA fromChIP with or without anti-
body and from input sample (sonicated DNA not included in the ChIP reaction)
was used for real-time PCR using Applied Biosystems 7300 real-time PCR
System and Power SYBR Green PCR Master Mix from Applied Biosystems.
Several sets of primers were used for Sox2 (see Figure 7). The PCR reaction
(25 ml) was started by a step of 10 min at 95C followed by 35 cycles of 15 s,
95C, 1 min 60C. Quantifications used data from the qPCR. Data are pre-
sented as percentage of input (see above). Threshold value for positive signals
was set at 0.1% of input (dashedline on the histograms).
qPCR
SVZs of pups and adults were dissected under binocular microscope, snap-
frozen in liquid nitrogen, and stored (80C) until processed. Total RNA was
extracted with RNAble (Eurobio, Les Ulis, France). Total RNA concentrations
were measured and RNAs were stored in Tris 10 mM/EDTA 0.1 mM (pH 7.4)
at 80C. To quantify mRNAs, 1 mg of total RNA was reverse-transcribed
using high capacity cDNA Reverse Transcription kit (Applied Biosystems,Cell Stem Cell 10, 531–543, May 4, 2012 ª2012 Elsevier Inc. 541
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done in parallel. Primers from Taqman Gene expression assays were used
for the mRNA detection of the following: Sox2 (Mm03053810_s1), cyclinD1
(Mm00432360_m1), Nestin (Mm01223404_g1), Msi1 (Mm00485224_m1),
Cspg4 (also called NG2; Mm00507256_m1), Ascl1 (also called Mash1;
Mm03058063_m1), elavl4 (also called hud; Mm00516018_m1), and control
assays (Gapdh; Mm99999915_g1). Primers for TRa1 and TRa2 were designed
in the laboratory (Hassani et al., 2007) and purchased from MWG Biotech
(Roissy CDG, France).
Direct detection of the PCR product was monitored by measuring the
increase in fluorescence generated by the TaqMan probe (Sox2, CyclinD1,
Nestin,Msi1, NG2,Mash1, elavl4, or Gapdh) or by the binding of SYBR Green
to dsDNA (TRa1 or TRa2) as described previously by Decherf et al. (2010).
Statistical Analysis
All experiments had n < 30; therefore, statistical analysis used nonparametric,
exact permutation tests (StatXact9, Cytel Studio software). This analysis
carries out permutations on exact values and is more powerful that the
Mann Whitney test. Note that for a population with normality, the median is
equal to the mean. Statistical differences were analyzed with appropriate
tests, indicated in figure legends, to compare control and treated group. p <
0.05 was considered significant (*p < 0.05; **p < 0.01; ***p < 0.001).
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